• 1
    Chen HF, Wu JP, Xu DS, Luo HY, Daloze PM. Reversal of ongoing heart, kidney and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993;56, 661 666
  • 2
    Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin distribution pharmacokinetics and therapeutic range investigations. Ther Drug Monit 1995;17, 666 671
  • 3
    Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative. Synergism with cyclosporine. Transplantation 1997;64, 32 35
  • 4
    Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 1997;64, 36 42
  • 5
    Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16, 31 34
  • 6
    Jean C & Laplanche RMethod of determination of SDZ RAD in blood by liquid chromatography/atmospheric pressure chemical ionization/mass spectrometry (HPLC/APCI/MS). Method description and preliminary validation. Basel: Novartis Pharma AG 1997.
  • 7
    Gibaldi M & Perrier F. Pharmacokinetics. Drugs and the Pharmaceutical Sciences, Vol 15. New York and Basel: Marcel Dekker Inc 1982.
  • 8
    Murgia MG, Jordan S, Kahan BD. The side effect profile of Sirolimus: a phase I study in quiescent cyclosporine-treated renal transplant patients. Kidney Int 1996;47, 209 216
  • 9
    Brattström C, Säwe J, Tydén G, et al. Kinetics and dynamics of single oral doses of Sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997;19, 397 406